DrugPatentWatch Database Preview
Drugs in Development Information for Sotrastaurin
» See Plans and Pricing
What is the drug development status for Sotrastaurin?
Sotrastaurin is an investigational drug.
There have been 6 clinical trials for Sotrastaurin.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2009.
The most common disease conditions in clinical trials are Melanoma, Uveal Neoplasms, and Lymphoma. The leading clinical trial sponsors are Novartis Pharmaceuticals, James Blachly, and Novartis.
Summary for Sotrastaurin
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 46 |
| WIPO Patent Applications | 34 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2009-12-01) |
| Vendors | 46 |
Recent Clinical Trials for Sotrastaurin
| Title | Sponsor | Phase |
|---|---|---|
| Trial of AEB071 in Combination With BYL719 in Patients With Melanoma | Richard D. Carvajal | Phase 1 |
| A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma | Array BioPharma | Phase 1/Phase 2 |
| Efficacy, Safety, Tolerability, Pharmacokinetics of Sotrastaurin-tacrolimus vs. Mycophenolic Acid-tacrolimus in de Novo Liver Transplant Patients | Novartis Pharmaceuticals | Phase 2 |
Clinical Trial Summary for Sotrastaurin
Top disease conditions for Sotrastaurin
Top clinical trial sponsors for Sotrastaurin
US Patents for Sotrastaurin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
